A recent study shows the impact of sarcopenia on patients with non-metastatic breast cancer.

Research in Review

A study of patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) metastatic breast cancer has found that treatment with first-line chemotherapy offers no survival benefit compared with hormone therapy, despite having significantly higher associated costs.

Read More

Results from a phase 2 clinical trial showed that combination neratinib and paclitaxel treatment better managed central nervous system progression versus trastuzumab and paclitaxel in patients with ERBB2-positive metastatic breast cancer.

Read More

Human epidermal growth factor receptor-2 (HER-2) expression may be a key indicator of recurrence risk in patients with breast cancer, though PIK3CA mutations have no prognostic value, according to a recent study. 

Read More

Subscribe to Breast Cancer